Kamada Ltd. (KMDA)
KMDA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1567529/000121390026025934/0001213900-26-025934-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | KMDA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | 2013 |
| SEC CIK | 0001567529 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Israel |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $180.5M |
| Net income | $20.2M |
| Operating income | $26.2M |
| Net margin | 11.2% |
| Operating margin | 14.5% |
| Revenue growth | +12.1% |
| Cash | $75.5M |
| Total assets | $378.7M |
| P/E (computed) | 23.2× |
| P/S (computed) | 2.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-11 |
| Cash and burn | $75.5M cash; operating cash flow $6.4M a quarter. | Report 2025-12-31 |
| Shares outstanding | 57,686,056 (2025-12-31); 57,505,031 a year earlier; 44,832,843 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-09-09 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Kost Forer Gabbay & Kasierer, Tel Aviv, Israel | PCAOB Form AP 2026-04-11 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $180.5M | $20.2M | $25.5M | $75.5M | No debt tags | $180.5M | 20-F 2026-03-11 |
| FY 2024 2024-12-31 | $161.0M | $14.5M | $47.6M | $78.4M | No debt tags | $161.0M | 20-F 2026-03-11 |
| FY 2023 2023-12-31 | $142.5M | $8.3M | $4.3M | $55.6M | No debt tags | $142.5M | 20-F 2026-03-11 |
| FY 2022 2022-12-31 | $129.3M | -$2.3M | $28.6M | $34.3M | $4.4M | $129.3M | 20-F 2025-03-05 |
| FY 2021 2021-12-31 | $103.6M | -$2.2M | -$8.8M | $18.6M | $3.8M | $103.6M | 20-F 2024-03-06 |
| FY 2020 2020-12-31 | $133.2M | $17.1M | $19.1M | $70.2M | $238K | $133.2M | 20-F 2023-03-15 |
| FY 2019 2019-12-31 | $127.2M | $22.3M | $27.6M | $42.7M | $489K | $127.2M | 20-F 2022-03-15 |
| FY 2018 2018-12-31 | $114.5M | $22.3M | $10.5M | $18.1M | $452K | $114.5M | 20-F 2021-02-24 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | F-3 | 2026-09-09 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-03-11 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-11-09 |
Source: SEC EDGAR submissions feed, 539 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +11.9% |
| 1 month | +5.2% |
| 3 months | +11.4% |
| Year to date | +14.6% |
| 1 year | +14.3% |
| From 52-week high | -13.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LYEL | Lyell Immunopharma Inc. | $14.65 | +2.45% | $469.0M |
| OCS | Oculis Holding AG | $7.63 | -0.13% | $469.9M |
| AQST | Aquestive Therapeutics Inc. | $3.76 | -3.84% | $472.6M |
| STTK | Shattuck Labs Inc. | $4.66 | +0.21% | $474.6M |
| PHAT | Phathom Pharmaceuticals Inc. | $5.88 | -2.97% | $478.0M |
| NGNE | Neurogene Inc. Common Stock | $23.30 | -2.63% | $482.3M |
| CAPR | Capricor Therapeutics Inc. | $8.30 | -12.91% | $482.6M |
| OVID | Ovid Therapeutics Inc. | $2.40 | -5.51% | $453.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier